# Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

> **NCT01250470** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 9 (actual)

## Conditions studied

- Anaplastic Astrocytoma
- Anaplastic Oligoastrocytoma
- Anaplastic Oligodendroglioma
- Giant Cell Glioblastoma
- Glioblastoma
- Gliosarcoma
- Mixed Glioma
- Recurrent Brain Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Montanide ISA-51/Survivin Peptide Vaccine
- **BIOLOGICAL:** Sargramostim

## Key facts

- **NCT ID:** NCT01250470
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-05
- **Primary completion:** 2014-05-29
- **Final completion:** 2014-05-29
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01250470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01250470, "Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01250470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*